TITLE

Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System

AUTHOR(S)
Letendre, Scott; Ellis, Ronald J.; Best, Brookie; Bhatt, Archana; Marquie-Beck, Jennifer; LeBlanc, Shannon; Rossi, Steven; Capparelli, Edmund; McCutchan, J. Allen
PUB. DATE
June 2009
SOURCE
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Jun2009, Vol. 8 Issue 2, p169
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Combination antiretroviral therapy (ART) has markedly reduced morbidity and mortality among HIV-infected individuals but not the prevalence of HIV-associated neurocognitive disorders (HAND). Several conditions may be responsible for the high prevalence of cognitive impairment, including incomplete suppression of HIV in nervous system by some antiretrovirals. Since individuals with HAND have a lower quality of life, worse medication adherence, and a higher risk of death, optimizing treatment of neurocognitive outcomes is an important goal of therapy. Optimization of ART to treat the CNS is limited, in part, by the ability of many antiretrovirals to cross the blood-brain barrier (BBB). Differences between antiretrovirals in crossing the BBB -- and by extension differences in their concentrations in the brain -- may explain inter-individual differences in susceptibility to HAND among treated individuals. This manuscript reviews relevant data on the CSF pharmacology of antiretrovirals and accumulating evidence that the use of drugs that reach therapeutic concentrations in the CNS are the best options to prevent and treat HIV-induced brain injury. Despite the importance of healthy cognition to the quality of patients' lives, consensus treatment guidelines for HAND have yet to be formulated more than two decades after its first description. Formulating widely accepted recommendations for CNS-optimized treatment strategies requires a level of clinical evidence not yet developed but studies are underway to address this shortcoming.
ACCESSION #
52345787

 

Related Articles

  • Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Gutierrez, Absalon; Balasubramanyam, Ashok // Endocrine (1355008X);Feb2012, Vol. 41 Issue 1, p1 

    HIV-infected patients on highly active antiretroviral therapy (HAART) have increased prevalence of a number of chronic metabolic disorders of multifactorial but unclear etiology. These include disorders of lipid metabolism with or without lipodystrophy, insulin resistance, and an increased...

  • Does antiretroviral therapy for HIV reduce the risk of developing multiple sclerosis? van der Kop, Mia L. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2015, Vol. 86 Issue 1, p3 

    The article presents a case study that examines the association of HIV and its treatment with antiretroviral therapy (ART) on multiple sclerosis (MS). Topics discussed include use of data of HIV patients between 1999 and 2011 followed up with records of MS, authors of the study showing that the...

  • Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera/Eviplera) in the treatment of HIV infection. Bernardini, Claudia; Maggiolo, Franco // Patient Preference & Adherence;2013, Vol. 7, p531 

    The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a oncedaily, single-tablet regimen (STR) containing one nonnucleoside reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved by regulatory agencies (eg, US Food...

  • NIGELLA SATIVA CONCOCTION INDUCED SUSTAINED SEROREVERSION IN HIV PATIENT. Adekunle Onifade, Abdulfatah; Jewell, Andrew Paul; Adeola Adedeji, Waheed // African Journal of Traditional, Complementary & Alternative Medi;2013, Vol. 10 Issue 5, p332 

    Nigella sativa had been documented to possess many therapeutic functions in medicine but the least expected is sero-reversion in HIV infection which is very rare despite extensive therapy with highly active anti-retroviral therapy (HAART). This case presentation is to highlight the complete...

  • ICAAC 2009: studies confirm the benefits of early initiation of therapy for HIV.  // PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p9 

    The article focuses on the benefits of early initiation of highly active antiretroviral therapy in early diagnosed HIV patients. There has been increasing evidence on the benefits of earlier treatment initiation and that the studies presented at the 2009 Interscience Conference on Antimicrobial...

  • Retention in Opioid Substitution Treatment: A Major Predictor of Long-Term Virological Success for HIV-Infected Injection Drug Users Receiving Antiretroviral Treatment. Roux, Perrine; Carrieri, M. Patrizia; Cohen, Julien; Ravaux, Isabelle; Poizot-Martin, Isabelle; Dellamonica, Pierre; Spire, Bruno // Clinical Infectious Diseases;11/1/2009, Vol. 49 Issue 9, p1433 

    Background. The positive impact of opioid substitution treatment (OST) on opioid-dependent individuals with human immunodeficiency virus (HIV) infection is well documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year...

  • The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy. Waters, Laura J.; Scourfield, Andrew T.; Marcano, Marie; Gazzard, Brian G.; Bower, Mark; Nelson, Mark; Stebbing, Justin // Clinical Infectious Diseases;3/1/2011, Vol. 52 Issue 5, p671 

    CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze...

  • Bisson GP et al (Clin Infect Dis 2013; 56:1165–73).  // Clinical Infectious Diseases;Oct2013, Vol. 57 Issue 7, p1067 

    A correction to the article "Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis" that was published in the April 15, 2013 issue is presented.

  • A Case of Cerebrospinal Fluid Viral Escape on a Dual Antiretroviral Regimen: Worth the Risk? Mangioni, Davide; Muscatello, Antonio; Sabbatini, Francesca; Soria, Alessandro; Rossi, Marianna; Bisi, Luca; Squillace, Nicola; De Grandi, Carlo; Gori, Andrea; Bandera, Alessandra // Clinical Infectious Diseases;Dec2014, Vol. 59 Issue 11, p1655 

    A letter to the editor is presented related to a case study of a 47-year-old HIV patient receiving antiretroviral therapy (ART) who developed cerebrospinal fluid (CSF) viral escape.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics